Table 2.
Clinical, pathological, and molecular characteristics of urothelial cancer according to tumor microenvironment immune types based on PD-L1 and CD8 T-Cell infiltration
| TMIT I | TMIT II | P | TMIT III | P | TMIT Ⅳ | P | |
|---|---|---|---|---|---|---|---|
| No. | 150 | 150 | 54 | 54 | |||
| Age | 72.19±18.15 | 73.01±16.74 | 0.683 | 67.37±24.83 | 0.195 | 70.80±19.29 | 0.632 |
| Gender | 0.514 | 0.517 | 0.86 | ||||
| Male | 107(71.3%) | 113(75.3%) | 41(75.9%) | 40(74.1%) | |||
| Female | 43(28.7%) | 37(24.7%) | 13(24.1%) | 14(25.9%) | |||
| Stage | |||||||
| I | 0 | 1(0.7%) | / | 1(1.9%) | / | 0 | / |
| II | 46(30.7%) | 51(34.0%) | 0.511 | 16(29.6%) | 0.948 | 17(31.5%) | 0.912 |
| III | 58(38.7%) | 49(32.7%) | 0.297 | 16(29.6%) | 0.270 | 17(31.5%) | 0.348 |
| Ⅳ | 46(30.7%) | 48(32.0%) | 0.773 | 20(37.0%) | 0.345 | 20(37.0%) | 0.391 |
| High grade | 148(99.3%) | 135(90.0%) | *** | 48(92.3%) | * | 53(98.1%) | 0.462 |
| FGFR3-mut | 8(5.3%) | 38(25.3%) | *** | 4(7.4%) | 0.522 | 10(18.5%) | ** |
| RB1-mut | 40(26.7%) | 14(9.0%) | *** | 10(18.5%) | 0.233 | 7(13.0%) | * |
| Mutation burden | 412.23±354.62 | 297.01±312.47 | ** | 372.81±645.67 | 0.581 | 353.48±269.44 | 0.27 |
| PD-L1 CNA | |||||||
| Amplication | 57(38.0%) | 15(10.0%) | *** | 11(20.4%) | * | 3(5.6%) | *** |
| Deletion | 36(24.0%) | 84(56.0%) | *** | 18(33.3%) | 0.158 | 36(66.7%) | *** |
| mRNA expression | |||||||
| CD8A | 7.06±8.05 | 0.42±0.29 | *** | 0.63±0.31 | *** | 2.36±1.41 | *** |
| PD-L1 | 6.65±6.68 | 0.39±0.22 | *** | 3.09±3.72 | *** | 0.54±0.22 | *** |
| IFN-γ | 1.53±2.17 | 0.04±0.06 | *** | 0.01±0.10 | *** | 0.23±0.25 | *** |
| TIGIT | 2.04±1.78 | 0.28±0.30 | *** | 0.37±0.28 | *** | 0.84±0.62 | *** |
| Cytolytic activity | 14.23±15.58 | 1.69±6.13 | *** | 2.16±2.75 | *** | 3.49±2.41 | *** |
| Neoantigen number | 51.86±48.52 | 38.93±30.44 | 0.146 | 36.38±0.28 | 0.267 | 50.21±41.78 | 0.895 |
The cytolytic activity of each sample was calculated using the value of the geometric mean of granzyme and perforin1. The predicted neoantigen number was referenced in a previous report by Chan-Young Ock. TCGA, the Cancer Genome Atlas; TMIT, tumor microenvironment immune type; mut, mutation; P: P value compared to TMIT I; CNA, copy number alteration; x±σ, mean ± standard deviation; ***, P < 0.001; **, P < 0.01; *, P < 0.05.